➡️ Semaglutide 2.4mg (Wegovy) now FDA-approved for MASH & stage 2-3 fibrosis❣️
Note:
1️⃣ Higher dose than what is used for diabetes
2️⃣ No approval in cirrhosis
MASH Management | Wegovy® (semaglutide) Injection 2.4 mg https://t.co/c6ndl2L2Kd
يطيب لنا في سلسلة لقاءات #تجربة_باحث استضافة هيلين هوانغ @HelenYRHuang من الكلية الملكية للجراحين في أيرلندا، والتي تميزت مسيرتها الأكاديمية بمساهماتها وخبرتها البحثية الفريدة في المعلوماتية الصحية وعلم الوراثة البشرية💫
📆 يو�� الثلاثاء ١٤ يناير، الساعة ٨ مساءً
لا تفوتوا فرصة التعرف على مسيرتها الحافلة بالمنجزات البحثية والمهنية المُلهمة لكل باحث متطلع✨
🟪NEW Article in press❕
Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach
🔓#OpenAccess at 👉https://t.co/kuvC3xbq9H
#LiverTwitter#MASLD#MASH
Can’t believe I’m already halfway through my last elective w/ the GI consult service at @MayoClinicGIHep. Been really taking in the amazing teaching, morning views and patient interactions! Gotta keep brushing up on standard of care practices for 💩😎
2/3 of my electives done! I’m really falling in love with Internal Medicine AND Philly after my sub internship! Thankful for the experience and friendships I’ve forged❤️🩺 @ImPennsy@PennMedicine!
Wrapped up my 4 week elective in transplant hep & GI with @VCU_Liver! I am grateful for the support from @ArunJSanyalVCU, @RichSterlingMD, @saulkarpen, Dr Lee and the entire GI/hepatology team as well as the @RCSI_Irl Alumni Clinical Elective Grant! 🩺🏥✨
📢Hot off the press: Think you know everything about TM6SF2? Meet ERLIN1! https://t.co/t5wJchvksW
Great study by our excellent student Miriam Rendel with @CV_Pharmd_PhD @ktc_phd David Zhang @EScorletti@HelenYRHuang@JoeInGenes @VellMara @KM_Schneider1 (1/3)